The effects of anisodamine and dobutamine on gut mucosal blood flow during gut ischemia/ reperfusion.
OBJECTIVE
To determine if anisodamine is able to augment mucosal perfusion during gut I/R ischemia-reperfusion.


METHODS
A jejunal sac was formed in Sprague Dawley rat. A Laser Doppler probe and a tonometer were inserted into the sac which was filled with saline. The superior mesenteric artery was occluded (SMAO)for 60 minutes followed by 90 minutes of reperfusion. At the end of 60 minutes of SMAO, either 0.2 mg/kg of anisodmine or dobutamine was injected into the jejunal sac. Laser Doppler mucosal blood flow and regional PCO2 (PrCO2)measurements were made.


RESULTS
Mucosal blood flow was significantly increased at 30,60 and 90 minutes of reperfusion (R30, R60, R90) when intraluminal anisodamine or dobutamine was present compared to intraluminal saline only(44+/-3.3% or 48+/-4.1% vs 37+/-2.6% at R30, 57+/-5.0% or 56+/-4.7% vs 45+/-2.7% at R60, 64+/-3.3% or 56+/-4.2% vs 48+/-3.4% at R90,respectively P<0.05). Blood flow changes were also reflected by lowering of jejunal PrCO2 measurements after intraluminal anisodamine or dobutamine compared with that of the saline controls (41+/-3.1 mmHg or 44+/-3.0 mmHg vs 49+/-3.7 mmHg at R30,38+/-3.7 mmHg or 40+/-2.1 mmHg vs 47+/-3.8 mmHg at R60,34+/-2.1 mmHg or 39+/-3.0 mmHg vs 46+/-3.4 mmHg at R90, respectively, P<0.05). Most interesting finding was that there were significantly higher mucosal blood flow and lower jejunal PrCO2 in anisodamine group than those in dobutamine group at 90 minutes of reperfusion(64+/-3.3% vs 56+/-4.2% for blood flow or 34+/-2.1 mmHg vs 39+/-3.0 mmHg for PrCO2, respectively, P<0.05), suggesting that anisodamine had a more lasting effect on mucosal perfusion than dobutamine.


CONCLUSIONS
Intraluminal anisodamine and dobutamine can augment mucosal blood flow during gut I/R and alleviate mucosal acidosis. The results provided beneficial effects on the treatment of splanchnic hypoperfusion following traumatic or burn shock.
Hu
Sen
S
Burns Institute, 304th Hospital of PLA, 51 Fu Cheng Road, Beijing 100037, China.
Sheng
Zhi-Yong
ZY
D000818:Animals; D002245:Carbon Dioxide / Q000378:metabolism; D004280:Dobutamine / Q000494:pharmacology*; D007413:Intestinal Mucosa / Q000098:blood supply / Q000187:drug effects; D007511:Ischemia / Q000188:drug therapy / Q000503:physiopathology; D007583:Jejunum / Q000098:blood supply* / Q000187:drug effects*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012039:Regional Blood Flow / Q000187:drug effects; D015427:Reperfusion Injury / Q000188:drug therapy / Q000503:physiopathology; D012991:Solanaceous Alkaloids / Q000494:pharmacology*
D012991:Solanaceous Alkaloids; C003922:anisodamine; D002245:Carbon Dioxide; D004280:Dobutamine